Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClearPoint NeuroCLPT -0.67%63 Debt-to-Equity is 5.93 as of Jun. 2026, which is 940% above its 10-year median of 0.57. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review. Among 703 Medical Devices & Instruments companies, ClearPoint Neuro ranks worse than 98.29% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ClearPoint Neuro's Debt-to-Equity or its related term are showing as below:
CLPT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.94 Med: 0.57 Max: 121.2
Current: 5.93
During the past 13 years, the highest Debt-to-Equity Ratio of ClearPoint Neuro was 121.20. The lowest was -5.94. And the median was 0.57.
CLPT's Debt-to-Equity is ranked worse than 98.29% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs CLPT: 5.93
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
ClearPoint Neuro Debt-to-Equity Related Terms
ClearPoint Neuro Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for ClearPoint Neuro's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ClearPoint Neuro's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClearPoint Neuro Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (CLPT) has a Debt-to-Equity of 5.93 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ClearPoint Neuro and its competitors. This is 940% above median its historical median of 0.57. According to the industry distribution chart, ClearPoint Neuro ranks #691 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 98.3%.
Is ClearPoint Neuro's Debt-to-Equity too high?
ClearPoint Neuro's current Debt-to-Equity of 5.93 is 940% above median its 10-year median of 0.57. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. ClearPoint Neuro's value of 5.93 is 2478.3% above this industry median. Based on the distribution chart, ClearPoint Neuro ranks #691 out of 703 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Debt-to-Equity compare to SI and PACB?
According to the Medical Devices & Instruments industry distribution chart, ClearPoint Neuro ranks #691 out of 703 companies for Debt-to-Equity. This places ClearPoint Neuro in the lower half of its industry. The industry median Debt-to-Equity is 0.23. ClearPoint Neuro's value of 5.93 is 2478.3% above this benchmark. While the company's 10-year median is 0.57 vs. the industry median of 0.23, ClearPoint Neuro has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ClearPoint Neuro's current Debt-to-Equity of 5.93 is 2478.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ClearPoint Neuro and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClearPoint Neuro's current Debt-to-Equity is 5.93, which is 940% above median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $14.79 — trading 4.6% above its estimated fair value. The current Debt-to-Equity is 5.93, which is 940% above median its 10-year median of 0.57 and 2478.3% above the Medical Devices & Instruments industry median of 0.23. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Debt-to-Equity is 5.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClearPoint Neuro (CLPT) Overvalued in 2026?
Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued.
The current stock price of $14.79 is trading 4.6% above its estimated GF Value™ of $14.14.
GuruFocus considers ClearPoint Neuro to be Fairly Valued.
Key valuation signals for CLPT:
Debt-to-Equity: 5.93 (940% above median its 10-year median of 0.57)
GF Value™: $14.14 vs. price of $14.79 (4.6% above fair value)
Industry Position: 2478.3% above the Medical Devices & Instruments median (#691 of 703)
No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score
Get the complete analysis for CLPT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPT has been successfully added to your 
